NanoInk Appoints James M. Hussey Chief Executive Officer

SKOKIE, IL, Jan 22 (MARKET WIRE) --
NanoInk, Inc. announced today the appointment of James M. Hussey, 48, as
its Chief Executive Officer, as well as a member of its Board of Directors.

Mr. Hussey joins NanoInk from Ovation Pharmaceuticals, Inc., a leading
biopharmaceutical company where he served on the senior management team. Mr.
Hussey will be a member of the external Advisory Board of Ovation and remain
involved with the company. Mr. Hussey is also an angel investor and has been
involved with or founded several early stage biotechnology companies including
Silamed
Pharmaceuticals, ProCor Pharmaceuticals and Barbeau Pharmaceuticals.

Prior to joining Ovation Pharmaceuticals, Mr. Hussey served as president and
chief
executive officer of NeoPharm, Inc., a biotechnology company specializing in the
research, development and marketing of cancer drugs. Mr. Hussey also served as a
director of Option Care, a local pharmacy infusion company, from 1999 until
2004.

Mr. Hussey began his career at Bristol-Myers Squibb in marketing, sales
andnew business development before being appointed to general manager in
1994.In 1995, he founded and served as chief executive officer of Physicians
Quality
Care, a physician management services organization in Oak Brook, Ill. which was
sold in 1998.

Mr. Hussey received a B.S. degree in Pharmacy from Butler University and a
Master of Business Administration degree from University of Illinois at
Chicago. He currently serves on the Board of the Illinois Biotechnology
Organization.

"We are delighted to have Jim lead the NanoInk team," said Mark Slezak,
Chairman
of the Company's Board of Directors. "He brings to us over two decades of
executive management, product development and marketing leadership at both small
and large pharmaceutical companies. His expertise and leadership will help
drive
NanoInk's growth in the future."

In accepting his appointment, Mr. Hussey said, "I am extremely excited about
the
opportunities of both Brand Protection and Dip Pen Nanolithography (DPN).
NanoInk is a high quality organization with an extremely promising future."

About NanoInk

NanoInk, Inc. is an emerging growth technology company specializing in
nanometer-scale manufacturing and applications development for the
lifescience and semiconductor industries. With DPN(R), a patented and
proprietary nanofabrication technology that allows for unmatched flexibility and
accuracy, and also its high-resolution Nanoencryption(TM) technology, NanoInk is
able to
offer its pharmaceutical customers innovative solutions to fight counterfeiting
and
illegal diversion of blockbuster pharmaceutical products. Other key
applications include nanoscale additive repair, and nanoscale rapid prototyping.

Located in the new Illinois Science + Technology Park, north of Chicago,
NanoInk currently has over 100 issued or pending patents and patent applications
filedworldwide and has licensing agreements with Northwestern University,
Stanford
University, the University of Illinois at Urbana-Champaign, and the Georgia
Institute of Technology. For more information on products and services
offered by NanoInk, Inc., see www.nanoink.net.

Contacts:
David Gutierrez
Dresner Corporate Services for NanoInk
312-780-7204
Email Contact

Joshua Taustein
Dresner Corporate Services for NanoInk
312-780-7219
Email Contact

Copyright 2008, Market Wire, All rights reserved.

-0-